Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18612579 | MEMBRANE-BOUND IL-12 FOR CELLULAR IMMUNOTHERAPY | March 2024 | June 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18394409 | METHODS OF TREATING A NEOPLASIA WITH IL-15-BASED MOLECULES AND CTLA-4 ANTIBODY | December 2023 | June 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18063871 | METHOD OF TREATING CANCER WITH COMPOSITION COMPRISING IL-15-BASED MOLECULES AND BCG | December 2022 | November 2023 | Allow | 11 | 2 | 0 | No | No |
| 18062109 | BCMA TARGETTING ANTIBODIES, CHIMERIC ANTIGEN RECEPTORS, AND USES THEREOF | December 2022 | March 2024 | Allow | 15 | 2 | 1 | Yes | No |
| 18045572 | COMPOSITIONS COMPRISING IL-15-BASED MOLECULES AND IMMUNE CHECKPOINT INHIBITOR ANTIBODIES | October 2022 | March 2024 | Allow | 17 | 3 | 0 | Yes | No |
| 17822598 | ANTI-CD30L ANTIBODIES AND USES THEREOF | August 2022 | August 2023 | Allow | 12 | 1 | 1 | Yes | No |
| 17820682 | ANTI-OX40 ANTIBODY AND USES THEREOF | August 2022 | February 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 17818840 | ANTI-TIGIT AND ANTI-CD96 ANTIBODIES | August 2022 | March 2023 | Allow | 7 | 0 | 1 | Yes | No |
| 17816946 | METHODS OF TREATING LUPUS NEPHRITIS BY ADMINISTRAITON OF TYPE II ANTI-CD20 ANTIBODIES | August 2022 | October 2024 | Abandon | 26 | 3 | 0 | Yes | No |
| 17734904 | METHODS FOR TREATING CANCER BY ACHIEVING THERAPEUTICALLY EFFECTIVE DOSES OF ANTI-CD47 ANTIBODY | May 2022 | November 2022 | Allow | 6 | 2 | 0 | Yes | No |
| 17734949 | METHODS FOR TREATING CANCER BY ACHIEVING THERAPEUTICALLY EFFECTIVE DOSES OF ANTI-CD47 ANTIBODY | May 2022 | September 2022 | Allow | 4 | 1 | 0 | No | No |
| 17727220 | METHODS OF TREATMENT USING CCR8 ANTIBODIES | April 2022 | January 2024 | Allow | 21 | 3 | 0 | Yes | No |
| 17677339 | ANTI-TNFRSF9 ANTIBODIES AND USES THEREOF | February 2022 | March 2024 | Abandon | 24 | 0 | 1 | No | No |
| 17670917 | CD137- AND DLL3-TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES | February 2022 | December 2022 | Allow | 10 | 1 | 0 | Yes | No |
| 17555282 | MULTIMERIC CD40 BINDING MOLECULES AND USES THEREOF | December 2021 | July 2024 | Abandon | 31 | 1 | 1 | No | No |
| 17546208 | METHOD OF TREATING A TUMOR USING ANTI-TfR ANTIBODIES | December 2021 | March 2024 | Allow | 27 | 1 | 1 | Yes | No |
| 17411953 | TREATMENT OF CANCER WITH DUAL TARGETING OF CD47 AND EGFR | August 2021 | March 2024 | Allow | 31 | 1 | 1 | Yes | No |
| 17410832 | TRAILshort ANTIBODY AND METHODS OF USE | August 2021 | May 2024 | Allow | 32 | 1 | 0 | Yes | No |
| 17394900 | Multivalent and Multispecific DR5-Binding Fusion Proteins and Methods of Modulating Immune Cells | August 2021 | January 2024 | Allow | 29 | 1 | 1 | Yes | No |
| 17358841 | CCR8 ANTIBODIES FOR THERAPEUTIC APPLICATIONS | June 2021 | February 2022 | Allow | 8 | 1 | 1 | Yes | No |
| 17324751 | ANTI-PD-1 ANTIBODIES AND USES THEREOF | May 2021 | February 2022 | Allow | 9 | 1 | 1 | Yes | No |
| 17290401 | BISPECIFIC ANTIBODY BINDING BCMA AND CD3 | April 2021 | February 2024 | Allow | 34 | 1 | 0 | Yes | No |
| 17238842 | BINDING MEMBERS TO TNF ALPHA | April 2021 | March 2024 | Abandon | 35 | 1 | 0 | No | No |
| 17239056 | TREATMENT OF CANCER WITH LARAZOTIDE DERIVATIVES IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS | April 2021 | December 2021 | Allow | 8 | 1 | 0 | Yes | No |
| 17229303 | EGFR BLOCKING AGENTS FOR THE THERAPEUTIC TREATMENT OF MYOPIA | April 2021 | April 2024 | Allow | 36 | 2 | 1 | Yes | No |
| 17216981 | CD3-TARGETING AND DLL3-TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF | March 2021 | November 2021 | Allow | 8 | 1 | 1 | Yes | No |
| 17206730 | HUMANIZED ANTI-CD137 ANTIBODIES AND USES THEREOF | March 2021 | August 2021 | Allow | 5 | 0 | 0 | Yes | No |
| 17200021 | ANTI-TNFRSF9 ANTIBODIES AND USES THEREOF | March 2021 | November 2021 | Allow | 8 | 1 | 1 | Yes | No |
| 17193586 | ANTI-GITR ANTIBODIES AND USES THEREOF | March 2021 | June 2023 | Allow | 27 | 0 | 1 | Yes | No |
| 17193865 | MODIFIED T LYMPHOCYTES COMPRISING A CD52 ANTIBODY-INDUCIBLE CASPASE AND METHODS OF APOPTOSIS | March 2021 | July 2023 | Allow | 28 | 0 | 0 | Yes | No |
| 17188025 | TL1A ANTIBODIES AND METHODS OF TREATMENT | March 2021 | July 2023 | Allow | 28 | 1 | 1 | Yes | No |
| 17165818 | HIGHLY POTENT ANTIBODIES BINDING TO DEATH RECEPTOR 5 | February 2021 | September 2023 | Allow | 32 | 1 | 0 | Yes | No |
| 17263350 | METHOD FOR THE TREATMENT OF A TUMOR PATIENT WITH ADOPTIVE T CELL IMMUNOTHERAPY | January 2021 | October 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17112564 | Methods of Treating Multiple Myeloma with Bispecific Anti-BCMA x Anti-CD3 Antibodies | December 2020 | October 2023 | Allow | 35 | 1 | 0 | Yes | No |
| 17104370 | High Affinity Human Antibodies to Human Angiopoietin-2 | November 2020 | October 2023 | Abandon | 34 | 1 | 0 | No | No |
| 17102183 | METHODS FOR TREATING CANCER BY ACHIEVING THERAPEUTICALLY EFFECTIVE DOSES OF ANTI-CD47 ANTIBODY | November 2020 | May 2021 | Allow | 6 | 1 | 0 | Yes | No |
| 17084881 | TRAILR2 CDH17 BINDING MOLECULES FOR THE TREATMENT OF CANCER | October 2020 | August 2023 | Allow | 33 | 1 | 1 | Yes | No |
| 17078929 | ANTIBODY MOLECULES TO PD-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASES | October 2020 | February 2024 | Abandon | 40 | 2 | 0 | No | No |
| 17046884 | ANTI-CD27 ANTIBODIES AND USE THEREOF | October 2020 | June 2023 | Allow | 32 | 1 | 1 | Yes | No |
| 17046671 | BISPECIFIC ANTIBODY WITH PROLONGED HALF-LIFE AND ENHANCED ANTI-TUMOR EFFECT | October 2020 | May 2023 | Abandon | 31 | 0 | 1 | No | No |
| 17046388 | ANTIBODY BINDING TIM-3 AND USE THEREOF | October 2020 | June 2023 | Allow | 33 | 1 | 1 | Yes | No |
| 17062100 | THERAPEUTIC COMPOSITIONS COMPRISING ANTI-NRP2 ANTIBODIES | October 2020 | August 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 17062458 | TARGETED IL-12 HETERODIMERIC FC-FUSION PROTEINS | October 2020 | August 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 17045143 | ANTI-CD27 ANTIBODIES AND USES THEREOF | October 2020 | April 2024 | Allow | 42 | 2 | 1 | Yes | No |
| 17037732 | RECOMBINANT FUSION PROTEIN AND IMMUNOGENIC COMPOSITION | September 2020 | September 2023 | Abandon | 35 | 1 | 0 | No | No |
| 17031615 | ANTIBODIES AGAINST TL1A AND USES THEREOF | September 2020 | May 2023 | Abandon | 31 | 1 | 1 | No | No |
| 17041349 | ANTI-BCMA ANTIBODIES AND TREATMENT METHODS | September 2020 | January 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 16981321 | Anti-CD27 Antibody, Antigen-binding Fragment Thereof, and Medical Use Thereof | September 2020 | April 2023 | Abandon | 31 | 1 | 0 | No | No |
| 16975137 | Fusion Proteins Containing CD47 Antibodies and Cytokines | August 2020 | April 2023 | Abandon | 40 | 1 | 1 | No | No |
| 16997738 | USE OF TLR AGONIST AND ANTI-CD47 AGENT TO ENHANCE PHAGOCYTOSIS OF CANCER CELLS | August 2020 | January 2023 | Allow | 29 | 1 | 0 | Yes | No |
| 16993569 | Single-Chain Trail-Receptor Agonist Proteins | August 2020 | October 2022 | Abandon | 26 | 1 | 1 | No | No |
| 16969905 | THERAPEUTIC MOLECULES THAT BIND TO LAG3 AND PD1 | August 2020 | December 2023 | Allow | 40 | 2 | 1 | Yes | No |
| 16986742 | Immune Cells Expressing Membrane-Bound Interleukin 15 (mbIL15) and Uses Thereof | August 2020 | September 2022 | Allow | 25 | 1 | 0 | Yes | No |
| 16966848 | MASKED ACTIVATABLE CD137 ANTIBODIES | July 2020 | August 2023 | Allow | 37 | 2 | 1 | Yes | No |
| 16965229 | ANTIBODY MOLECULES COMPRISING A SINGLE-DOMAIN ANTIGEN-BINDING SITE AND FAB FRAGMENTS | July 2020 | April 2023 | Allow | 33 | 2 | 1 | No | No |
| 16963595 | ANTI-4-1BB ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF | July 2020 | October 2022 | Abandon | 27 | 0 | 1 | No | No |
| 16959981 | MULTI-SPECIFIC LIGAND BINDERS | July 2020 | March 2024 | Allow | 45 | 3 | 1 | Yes | No |
| 16959330 | Chimeric Antigen Receptor Specific for BDCA2 Antigen | June 2020 | May 2023 | Allow | 35 | 2 | 0 | Yes | No |
| 16911052 | CD137 ANTIBODIES FOR T-CELL ACTIVATION | June 2020 | March 2023 | Allow | 33 | 2 | 1 | Yes | No |
| 16905609 | CHIMERIC ANTIGEN RECEPTORS COMPRISING A HUMAN TRANSFERRIN EPITOPE SEQUENCE | June 2020 | March 2023 | Allow | 33 | 2 | 1 | No | No |
| 16762871 | 4-1BB ANTIBODY AND PREPARATION METHOD AND USE THEREOF | June 2020 | October 2022 | Allow | 29 | 2 | 0 | Yes | No |
| 16771402 | DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES COMPRISING INTERLEUKIN RECEPTOR SIGNALING DOMAINS | June 2020 | December 2023 | Allow | 42 | 2 | 1 | No | No |
| 16768447 | USE OF CD3XCLEC12A BISPECIFIC ANTIBODY AND IL-15 FOR COMBINATION THERAPY | May 2020 | September 2023 | Abandon | 40 | 2 | 1 | Yes | No |
| 16768500 | METHODS FOR USING CD137 LIGAND AS A BIOMARKER FOR TREATMENT WITH ANTI-CD137 ANTIBODY | May 2020 | March 2023 | Abandon | 34 | 1 | 1 | No | No |
| 16882800 | NUCLEIC ACIDS ENCODING CHIMERIC RECEPTOR COMPRISING NKP30 RECEPTOR AND CD28 AND CD3 zeta DOMAINS AND HUMAN T CELL CONTAINING | May 2020 | August 2023 | Allow | 39 | 2 | 0 | Yes | No |
| 16877938 | METHOD OF USING ANTI-CD47 ANTIBODY MOLECULES | May 2020 | February 2022 | Allow | 21 | 0 | 0 | Yes | No |
| 16876726 | HUMANIZED ANTIBODIES AGAINST CEACAM1 | May 2020 | August 2023 | Allow | 39 | 2 | 1 | Yes | No |
| 16871799 | PD-L1 AND OX40 BINDING PROTEINS FOR CANCER REGULATION | May 2020 | December 2022 | Allow | 31 | 2 | 1 | No | No |
| 16335971 | BINDING MOLECULES THAT BIND CD137 AND PD-L1 | May 2020 | November 2022 | Allow | 44 | 1 | 1 | Yes | No |
| 16866425 | SIRP-GAMMA POLYPEPTIDE COMPOSITIONS AND METHODS OF USE | May 2020 | May 2022 | Allow | 24 | 1 | 0 | Yes | No |
| 16760600 | CD137 ANTIBODIES AND PD-1 ANTAGONISTS AND USES THEREOF | April 2020 | February 2023 | Allow | 34 | 2 | 1 | Yes | No |
| 16760681 | TRIPLE-CHAIN ANTIBODY, METHOD FOR PREPARATION AND USE THEREOF | April 2020 | June 2023 | Abandon | 38 | 1 | 1 | No | No |
| 16760180 | CRTAM ANTIBODIES AND METHODS OF TREATING CANCER | April 2020 | February 2023 | Allow | 34 | 2 | 0 | Yes | No |
| 16759722 | ANTI-LAG-3 ANTIBODY AND USE THEREOF | April 2020 | March 2023 | Allow | 35 | 2 | 1 | No | No |
| 16857573 | POLYNUCLEOTIDES ENCODING RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS | April 2020 | September 2023 | Allow | 41 | 2 | 1 | Yes | No |
| 16610919 | CEA.CAR-T, PREPARATION METHOD THEREFOR AND USE THEREOF | April 2020 | January 2023 | Abandon | 39 | 0 | 1 | No | No |
| 16755091 | MODULATING THE IMMUNE RESPONSE USING ANTIBODY-DRUG CONJUGATES | April 2020 | January 2023 | Abandon | 34 | 2 | 0 | No | No |
| 16844747 | KILLER CELL LECTIN-LIKE RECEPTOR SUBFAMILY G MEMBER 1 (KLRG1) DEPLETING ANTIBODIES | April 2020 | July 2021 | Allow | 15 | 1 | 1 | Yes | No |
| 16753876 | ANTIBODIES TARGETING PDL1 AND METHODS OF USE THEREOF | April 2020 | April 2024 | Allow | 49 | 4 | 0 | Yes | No |
| 16841306 | ANTI-DR5 FAMILY ANTIBODIES, BISPECIFIC OR MULTIVALENT ANTI-DR5 FAMILY ANTIBODIES AND METHODS OF USE THEREOF | April 2020 | December 2023 | Abandon | 44 | 3 | 0 | No | No |
| 16830322 | LRP5 AND PD-1 ANTAGONIST ANTICANCER COMBINATION THERAPY | March 2020 | November 2022 | Allow | 32 | 2 | 1 | Yes | No |
| 16825773 | COMBINATION THERAPY WITH TARGETED 4-1BB (CD137) AGONISTS | March 2020 | April 2023 | Abandon | 37 | 1 | 2 | No | No |
| 16648731 | AGONISTIC CD40 ANTIBODIES | March 2020 | February 2023 | Allow | 35 | 2 | 1 | Yes | No |
| 16647973 | ANTI-YKL40 ANTIBODIES AND METHODS OF USE | March 2020 | March 2023 | Abandon | 35 | 2 | 1 | Yes | No |
| 16807539 | Method Treating Malignant Ascites and Metastatic Pleural Effusion with and Disulfide-Linked Trimeric TRAIL | March 2020 | June 2022 | Allow | 28 | 2 | 0 | Yes | No |
| 16803126 | Method for Treating Cancer Using Disulfide-Linked Trimeric 4-1BBL | February 2020 | April 2022 | Allow | 26 | 1 | 0 | Yes | No |
| 16642001 | TP53 AS BIOMARKER FOR RESPONSIVENESS TO IMMUNOTHERAPY | February 2020 | November 2022 | Abandon | 33 | 0 | 1 | No | No |
| 16798030 | MITIGATION AND REVERSAL OF INTESTINAL FIBROSIS AND INFLAMMATION BY INHIBITION OF TL1A FUNCTION | February 2020 | April 2022 | Allow | 26 | 1 | 0 | Yes | No |
| 16640684 | METHOD FOR TREATING CANCER USING ANTI-CD137 ANTIBODY | February 2020 | July 2023 | Allow | 41 | 3 | 1 | Yes | No |
| 16637524 | Cells Expressing Cell Surface Receptors and Antibodies | February 2020 | January 2023 | Abandon | 36 | 0 | 1 | No | No |
| 16750842 | ANTI-CD137 ANTIBODIES | January 2020 | July 2022 | Allow | 30 | 1 | 1 | Yes | No |
| 16631961 | PHOSPHATIDYLSERINE TARGETING FUSION MOLECULES AND METHODS FOR THEIR USE | January 2020 | February 2022 | Allow | 25 | 2 | 1 | Yes | No |
| 16737503 | TREATMENT OF SKIN DISORDERS WITH COMPOSITIONS COMPRISING AN EGFR INHIBITOR | January 2020 | December 2022 | Allow | 35 | 3 | 1 | No | No |
| 16626991 | ANTI-B-CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTORS WITH HUMAN DOMAINS | December 2019 | February 2024 | Abandon | 49 | 2 | 1 | No | No |
| 16626060 | MONOCLONAL ANTIBODY TARGETING HUMAN TUMOR STEM CELLS AND USE THEREOF | December 2019 | March 2023 | Allow | 38 | 1 | 1 | Yes | No |
| 16721485 | BAFF-R BISPECIFIC T-CELL ENGAGER ANTIBODY | December 2019 | May 2024 | Abandon | 53 | 4 | 1 | No | No |
| 16619891 | A COMBINATION OF, OR A BISPECIFIC BINDING MOLECULE TO, AN IMMUNE CHECKPOINT MOLECULE ANTAGONIST AND A RANK-L (NF-KB LIGAND) ANTAGONIST FOR CANCER THERAPY OR PROPHYLAXIS AND USES THEREOF | December 2019 | January 2024 | Abandon | 49 | 1 | 1 | No | No |
| 16618722 | THERAPEUTIC ANTIBODIES BASED ON MUTATED IGG HEXAMERS | December 2019 | December 2022 | Abandon | 37 | 1 | 1 | No | No |
| 16700490 | POLYNUCLEOTIDES ENCODING HUMANIZED ANTIBODIES AGAINST CEACAM1 | December 2019 | May 2022 | Allow | 29 | 0 | 0 | Yes | No |
| 16698701 | NOVEL ADMINISTRATION ROUTES FOR IMMUNE AGONISTS | November 2019 | September 2023 | Abandon | 45 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KAUFMAN, CLAIRE M.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 12.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KAUFMAN, CLAIRE M works in Art Unit 1646 and has examined 582 patent applications in our dataset. With an allowance rate of 50.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner KAUFMAN, CLAIRE M's allowance rate of 50.0% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KAUFMAN, CLAIRE M receive 1.64 office actions before reaching final disposition. This places the examiner in the 45% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by KAUFMAN, CLAIRE M is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +60.9% benefit to allowance rate for applications examined by KAUFMAN, CLAIRE M. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 25.5% of applications are subsequently allowed. This success rate is in the 31% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 50.3% of cases where such amendments are filed. This entry rate is in the 71% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 87.5% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 90.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 53.0% are granted (fully or in part). This grant rate is in the 66% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 7.4% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.5% of allowed cases (in the 80% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.